WOUND CARE PRODUCT SALES DRAWING ATTENTION, ACQUISITIONS, AND NEW
INVESTMENT, ANALYST SAYS
LOS ANGELES, Aug 5, 1999 /PRNewswire via COMTEX/ -- The following is
being issued by Wedbush Morgan Securities, a member of the National
Association of Securities Dealers, CRD Number 877. Wedbush Morgan
Securities is also a member of the New York Stock Exchange:
The two "wound glues" on the U.S. market and the five others preparing
to launch in the U.S. are drawing biotech investor attention back to
the wound care market, according to the firm covering this sector. The
entire wound care sector along with related fields including bone
fracture repair and implantable tissue products, has been broken down,
described, and rated in a newly-released Wedbush Morgan research
report.
Dr. Alexander Arrow, Vice President, Research at Wedbush Morgan has
issued the revised and greatly expanded fifth edition of his popular
report describing companies competing in each of nineteen sub-sectors
of wound care and related fields.
Originally a niche market thought to contain simply skin ulcer and burn
therapy products, the wound care sector has grown to include suture
alternatives, devices for sealing angioplasty entry sites, and
post-operative adhesion prevention. Now with Chiron's Regranex hitting
a $150 million annual run rate, Closure's Dermabond, Perclose's
Techstar and Prostar surpassing $50 million in end-user sales, and
Abbott Labs and St. Jude collectively spending $850 million acquiring
two wound care product lines, the sector is maturing.
The markets the report traditionally covers -- including diabetic foot
ulcers, post-angioplasty wound closure, severe burns, and skin wound
glue-- have been augmented this time with eight new categories. The new
categories are implantable tissue, incontinence therapy, brain membrane
repair, orthopedic injury repair, scar therapy devices, commodity wound
cleansers, injectables for facial augmentation, and the dry bandage
market.
The report analyzes the relative strengths and weaknesses of each
company. It also ranks each company's position in its market according
to three parameters: the strength of its product, the stage of its
development, and the reach of its distribution system.
Dr. Arrow's report then offers specific investment recommendations on 6
companies on the Wedbush Morgan wound care research list, and compares
features of 34 others, for a total of 40 companies (30 public and 10
private).
The six companies with formal research coverage are: Advanced Tissue
Sciences (ATIS), Bio-Technology General Corporation (BTGC), ConMed
Corporation (CNMD), Integra LifeSciences (IART), Organogenesis (ORG),
and Ortec (ORTC).
The other public wound care companies compared are: BioSpecifics
(BSTC), Carrington Laboratories (CARN), Chiron Corporation (CHIR),
Closure Medical (CLSR), Cohesion Technologies (CSON), Cryolife (CRY),
Cypros Pharmaceuticals (CYP), Datascope Corporation (DSCP), Derma
Sciences (DSCI), Focal (FOCL), Fusion Medical Technologies (FSON),
Genzyme Surgical Products (GZSP), Genzyme Tissue Repair (GZTR),
Gliatech (GLIA), Human Genome Sciences (HGSI), Kensey Nash (KNSY), Life
Medical Sciences (CHAI), LifeCell Corporation (LIFC), Lifecore
Biomedical (LCBM), Magainin Pharmaceuticals (MAGN), Perclose (PERC),
ProCyte (PRCY), ThermoGenesis (KOOL), and Vitex (VITX).
Larger companies with collaborations in wound care detailed in the
report include: Abbott Labs (ABT), Baxter (BAX), Bristol-Myers Squibb
(BMS), Johnson & Johnson (JNJ), Novartis (NVTSY), St. Jude (STJ), Tyco
(TYC), 3M Corporation(MMM).
To find out how to receive a copy of the report, contact a Wedbush
Morgan sales representative.
SOURCE Wedbush Morgan Securities
(C) 1999 PR Newswire. All rights reserved.
prnewswire.com -0-
CONTACT: Sunny Ommanney of Wedbush Morgan Securities,
213-688-4525
WEB PAGE: wedbush.com |
